Raymond James Initiates Coverage On INmune Bio with Outperform Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
Raymond James has initiated coverage on INmune Bio (NASDAQ:INMB) with an Outperform rating and set a price target of $18.
September 27, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has initiated coverage on INmune Bio with an Outperform rating and a price target of $18, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating by Raymond James suggests a positive sentiment towards INmune Bio's stock. The price target of $18 indicates potential upside, which is likely to attract investor interest and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100